Indapamide (Tablets, Capsules) Instructions for Use
ATC Code
C03BA11 (Indapamide)
Active Substance
Indapamide (Rec.INN registered by WHO)
Clinical-Pharmacological Group
Diuretic. Antihypertensive drug
Pharmacotherapeutic Group
Diuretics; thiazide-like diuretics, sulfonamides
Pharmacological Action
Thiazide-like diuretic, antihypertensive agent. It causes a decrease in the tone of arterial smooth muscles, a reduction in total peripheral vascular resistance, and also has a moderate saluretic activity due to impaired reabsorption of sodium, chloride, and water ions in the cortical segment of the loop of Henle and the proximal convoluted tubule of the nephron.
The reduction in total peripheral vascular resistance is due to several mechanisms: decreased sensitivity of the vascular wall to norepinephrine and angiotensin II; increased synthesis of prostaglandins with vasodilating activity; inhibition of calcium ion influx into the smooth muscle elements of the vascular wall. In therapeutic doses, it practically does not affect lipid and carbohydrate metabolism.
The hypotensive effect manifests only with initially elevated blood pressure, develops by the end of the first week, and reaches its maximum after 3 months of systematic administration.
Pharmacokinetics
After oral administration, it is rapidly and completely absorbed from the gastrointestinal tract. Cmax in plasma is reached after 1-2 hours. Plasma protein binding is 79%. It is widely distributed in the body. Does not accumulate.
T1/2 is 18 hours. It is excreted by the kidneys mainly in the form of metabolites, 5% – unchanged.
Indications
Arterial hypertension.
ICD codes
| ICD-10 code | Indication |
| I10 | Essential [primary] hypertension |
| ICD-11 code | Indication |
| BA00.Z | Essential hypertension, unspecified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administer orally, as tablets or capsules, once daily in the morning with a glass of water, with or without food. Maintain consistent daily intake timing.
The recommended initial and maintenance dose is 2.5 mg. Do not exceed the maximum daily dose of 2.5 mg. Higher doses do not enhance the antihypertensive effect but significantly increase diuretic activity and the risk of adverse effects.
Regularly monitor blood pressure and serum electrolyte levels, particularly potassium and sodium, especially during initial therapy and after dosage adjustments. Assess renal function periodically.
For elderly patients or those with impaired renal function, initiate therapy at the standard 2.5 mg dose with increased vigilance for electrolyte disturbances and signs of dehydration. Adjust therapy based on clinical response and tolerance.
In patients with severe hepatic impairment, the use of indapamide is contraindicated. Exercise caution in patients with mild to moderate liver dysfunction due to the risk of precipitating hepatic encephalopathy.
If a dose is missed, take it as soon as remembered on the same day. If it is near the time for the next dose, skip the missed dose and resume the usual dosing schedule. Do not take a double dose to make up for a forgotten one.
The full antihypertensive effect is typically achieved within 1 to 3 months of continuous therapy. Evaluate therapeutic response after 4 to 8 weeks. Discontinue treatment if effective blood pressure control is not attained.
Prior to elective surgery requiring general anesthesia, inform the anesthesiologist of indapamide use, as it may potentiate the effects of antihypertensive agents and increase the risk of arterial hypotension.
Adverse Reactions
From the hematopoietic system: very rarely – thrombocytopenia, leukopenia, agranulocytosis, aplastic anemia, hemolytic anemia.
From the nervous system: rarely – dizziness, fatigue, headache, paresthesia.
From the organ of vision: frequency unknown – myopia, blurred vision, visual impairment.
From the cardiovascular system: very rarely – arrhythmia, arterial hypotension; frequency unknown – torsades de pointes type arrhythmia.
From the digestive system: infrequently – vomiting; rarely – nausea, constipation, dry oral mucosa; very rarely – pancreatitis.
From the liver and biliary tract: very rarely – impaired liver function; frequency unknown – development of hepatic encephalopathy in case of hepatic insufficiency.
From the skin and subcutaneous tissues: hypersensitivity reactions, mainly dermatological, in patients with a predisposition to allergic and asthmatic reactions. Often – maculopapular rash; infrequently – purpura; very rarely – angioedema and/or urticaria, toxic epidermal necrolysis, Stevens-Johnson syndrome; frequency unknown – in patients with acute systemic lupus erythematosus, worsening of the disease course is possible, photosensitivity.
From the urinary system: very rarely – renal failure.
From laboratory parameters: very rarely – hypercalcemia; frequency unknown – increased QT interval on ECG, hyperuricemia, increased blood uric acid and glucose concentrations, increased activity of hepatic transaminases, decreased potassium content with the development of hypokalemia (especially important for patients in high-risk groups), hyponatremia with hypovolemia (leading to dehydration and orthostatic hypotension), hypochloremia (may cause secondary metabolic alkalosis).
Contraindications
Hypersensitivity to indapamide, other sulfonamide derivatives; severe renal failure; severe hepatic failure and hepatic encephalopathy; hypokalemia; pregnancy, breastfeeding period, age under 18 years (efficacy and safety not established).
With caution in cases of impaired liver and kidney function, water-electrolyte balance disorders, hyperparathyroidism, diabetes mellitus, hyperuricemia and gout; debilitated patients, ascites, coronary artery disease, chronic heart failure; in patients with prolonged QT interval or in patients receiving concurrent therapy with drugs that may prolong the QT interval.
Use in Pregnancy and Lactation
Contraindicated for use during pregnancy and lactation (breastfeeding).
Use in Hepatic Impairment
Contraindicated in severe hepatic failure and hepatic encephalopathy. Should be used with caution in patients with impaired liver function.
Use in Renal Impairment
Contraindicated in severe renal failure. Should be used with caution in patients with impaired renal function.
Pediatric Use
Use in children and adolescents under 18 years of age is contraindicated.
Geriatric Use
Should be prescribed with caution to elderly patients to avoid worsening of concomitant diseases.
Special Precautions
In case of impaired liver function, thiazide and thiazide-like diuretics can lead to the development of hepatic encephalopathy. In this case, the use of diuretics must be stopped immediately.
Cases of photosensitivity reactions have been reported with the use of thiazide and thiazide-like diuretics. If photosensitivity reactions develop during therapy, it is necessary to immediately discontinue indapamide. If continuation of diuretic therapy is necessary, it is recommended to protect the skin from exposure to sunlight or artificial ultraviolet rays.
The concentration of sodium ions in the blood plasma must be determined before starting treatment and then this indicator should be regularly monitored. Hyponatremia and hypovolemia can lead to dehydration and orthostatic hypotension. Concomitant decrease in chloride ion concentration can lead to secondary metabolic alkalosis. For patients with liver cirrhosis and elderly patients, more frequent monitoring of plasma sodium ion concentration is indicated.
Long-term use of thiazide and thiazide-like diuretics poses a risk of decreased plasma potassium concentration and the development of hypokalemia. It is necessary to prevent the risk of developing hypokalemia (< 3.4 mmol/L), especially in elderly patients, debilitated patients, or those receiving combined drug therapy, in patients with cirrhosis of the liver accompanied by edema and ascites, in patients with coronary artery disease and heart failure, since hypokalemia increases the likelihood of arrhythmia (hypokalemia in these patient groups enhances the toxic effect of cardiac glycosides). The risk of hypokalemia is also possible in patients with a prolonged QT interval. Hypokalemia predisposes to the occurrence of severe arrhythmias, especially the deadly polymorphic ventricular tachycardia of the ‘torsades de pointes’ type. It is necessary to regularly monitor the potassium content in the blood plasma in all the above cases.
Thiazide and thiazide-like diuretics can reduce the renal excretion of calcium ions, which can lead to a moderate and temporary increase in plasma calcium concentration.
It is necessary to regularly monitor plasma glucose concentration in patients with diabetes mellitus, especially in the presence of hypokalemia.
With increased uric acid concentration, gout attacks are possible; in such cases, the dose of indapamide should be adjusted accordingly.
Hypovolemia caused by the loss of fluid and sodium ions during diuretic treatment can cause a decrease in glomerular filtration, which may result in increased plasma concentrations of urea and creatinine.
Effect on the ability to drive vehicles and mechanisms
During the treatment period, patients who experience dizziness, fatigue, headache, or decreased blood pressure should refrain from driving vehicles and other activities requiring high concentration and speed of psychomotor reactions.
Drug Interactions
With simultaneous use of systemic corticosteroids, tetracosactide, the antihypertensive effect is reduced due to water and sodium ion retention under the influence of corticosteroids.
With simultaneous use with ACE inhibitors, the risk of developing hyponatremia increases.
There is a risk of developing sudden arterial hypotension and/or acute renal failure in combination with ACE inhibitors against the background of an already existing reduced plasma sodium ion concentration (especially in patients with renal artery stenosis).
With simultaneous use with systemic NSAIDs, a reduction in the antihypertensive effect of indapamide is possible. With significant fluid loss, acute renal failure may develop (due to a sharp decrease in glomerular filtration).
With simultaneous use with calcium preparations, the development of hypercalcemia is possible due to reduced excretion of calcium ions in the urine.
With simultaneous use with cardiac glycosides, corticosteroids, the risk of developing hypokalemia increases.
With simultaneous use of agents that can cause hypokalemia (amphotericin B, gluco- and mineralocorticoids, tetracosactide, stimulant laxatives), the risk of developing hypokalemia increases.
With simultaneous use with tricyclic antidepressants (including imipramine), the antihypertensive effect is enhanced and the risk of developing orthostatic hypotension increases (additive effect).
With simultaneous use with astemizole, bepridil, intravenous erythromycin, pentamidine, sultopride, terfenadine, vincamine, quinidine, disopyramide, amiodarone, bretylium tosylate, sotalol, there is a risk of developing torsades de pointes type arrhythmia.
With simultaneous use with baclofen, the antihypertensive effect is enhanced.
With simultaneous use with halofantrine, the likelihood of cardiac rhythm disturbances (including torsades de pointes type ventricular arrhythmia) increases.
With simultaneous use with lithium carbonate, the risk of developing the toxic effect of lithium increases against the background of a decrease in its renal clearance.
With simultaneous use with metformin, the appearance of lactic acidosis is possible, which is apparently associated with the development of functional renal failure caused by the action of diuretics (mainly ‘loop’ diuretics).
With simultaneous use with cyclosporine, an increase in plasma creatinine content is possible, which is observed even with normal water and sodium ion content.
Dehydration of the body while taking diuretics increases the risk of developing acute renal failure, especially when using high doses of iodine-containing X-ray contrast agents. It is necessary to compensate for fluid loss before the administration of an iodine-containing X-ray contrast agent.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Controlled-release tablets, film-coated, 1.5 mg: 20, 30, 40, 50, 60, 70, 80, or 90 pcs.
Marketing Authorization Holder
Izvarino Pharma LLC (Russia)
Dosage Form
 |
Indapamide Retard | Controlled-release tablets, film-coated, 1.5 mg: 20, 30, 40, 50, 60, 70, 80, or 90 pcs. |
Dosage Form, Packaging, and Composition
Controlled-release tablets, film-coated white or almost white, round, biconvex.
| 1 tab. | |
| Indapamide | 1.5 mg |
Excipients: mannitol – 90.75 mg, hypromellose – 51 mg, povidone K90 – 4.5 mg, magnesium stearate – 1.5 mg, colloidal silicon dioxide – 0.75 mg.
Film coating composition: Opadry II white (33G28435) – 5 mg (hypromellose – 40%, titanium dioxide – 25%, lactose monohydrate – 21%, macrogol – 8%, triacetin – 6%).
10 pcs. – contour cell packaging (2) – cardboard packs.
10 pcs. – contour cell packaging (3) – cardboard packs.
10 pcs. – contour cell packaging (4) – cardboard packs.
10 pcs. – contour cell packaging (5) – cardboard packs.
10 pcs. – contour cell packaging (6) – cardboard packs.
10 pcs. – contour cell packaging (7) – cardboard packs.
10 pcs. – contour cell packaging (8) – cardboard packs.
10 pcs. – contour cell packaging (9) – cardboard packs.
15 pcs. – contour cell packaging (2) – cardboard packs.
15 pcs. – contour cell packaging (4) – cardboard packs.
15 pcs. – contour cell packaging (6) – cardboard packs.
Extended-release tablets, film-coated, 1.5 mg: 10, 20, 30, 40, 60, 80, 90, or 120 pcs.
Marketing Authorization Holder
Canonpharma Production, CJS (Russia)
Dosage Form
|
Indapamide Retard | Extended-release tablets, film-coated, 1.5 mg: 10, 20, 30, 40, 60, 80, 90, or 120 pcs. |
Dosage Form, Packaging, and Composition
Extended-release tablets, film-coated white or almost white, round, biconvex; on the cross-section – almost white.
| 1 tab. | |
| Indapamide | 1.5 mg |
Excipients: hypromellose (hydroxypropyl methylcellulose) – 17 mg, Kollidon SR – 7.5 mg, incl. polyvinyl acetate – 6 mg, povidone – 1.425 mg, sodium lauryl sulfate – 0.06 mg, anhydrous colloidal silicon dioxide – 0.015 mg; copovidone – 6.6 mg, anhydrous colloidal silicon dioxide – 1.2 mg, lactose monohydrate – 69.9 mg, magnesium stearate – 1.3 mg, microcrystalline cellulose – 25 mg.
Film coating composition: Opadry II white – 4 mg (polyvinyl alcohol – 1.6 mg, macrogol (polyethylene glycol 3350) – 0.808 mg, talc – 0.592 mg, titanium dioxide – 1 mg).
10 pcs. – contour cell packaging (1) – cardboard packs.
10 pcs. – contour cell packaging (2) – cardboard packs.
10 pcs. – contour cell packaging (3) – cardboard packs.
10 pcs. – contour cell packaging (6) – cardboard packs.
20 pcs. – contour cell packaging (1) – cardboard packs.
20 pcs. – contour cell packaging (2) – cardboard packs.
20 pcs. – contour cell packaging (3) – cardboard packs.
20 pcs. – contour cell packaging (4) – cardboard packs.
30 pcs. – contour cell packaging (1) – cardboard packs.
30 pcs. – contour cell packaging (2) – cardboard packs.
30 pcs. – contour cell packaging (3) – cardboard packs.
30 pcs. – contour cell packaging (4) – cardboard packs.
Extended-release tablets, film-coated, 1.5 mg: 10, 20, 30, 40, 50, 60, 80, 90, 100, 120, 150, 180, 240, or 300 pcs.
Marketing Authorization Holder
Ozon, LLC (Russia)
Manufactured By
Ozon, LLC (Russia)
Or
Ozon Pharm, LLC (Russia)
Dosage Form
|
Indapamide Retard | Extended-release tablets, film-coated, 1.5 mg: 10, 20, 30, 40, 50, 60, 80, 90, 100, 120, 150, 180, 240, or 300 pcs. |
Dosage Form, Packaging, and Composition
Extended-release tablets, film-coated white or almost white, biconvex in shape; white or almost white on the break.
| 1 tab. | |
| Indapamide | 1.5 mg |
Excipients: lactose monohydrate – 136.5 mg, hypromellose – 60 mg, colloidal silicon dioxide – 1 mg, magnesium stearate – 1 mg.
Coating composition: hypromellose – 3.24 mg, titanium dioxide – 1.6 mg, macrogol-4000 – 1.16 mg.
10 pcs. – contour cell packaging (1) – cardboard packs.
10 pcs. – contour cell packaging (2) – cardboard packs.
10 pcs. – contour cell packaging (3) – cardboard packs.
10 pcs. – contour cell packaging (4) – cardboard packs.
10 pcs. – contour cell packaging (5) – cardboard packs.
10 pcs. – contour cell packaging (6) – cardboard packs.
10 pcs. – contour cell packaging (8) – cardboard packs.
10 pcs. – contour cell packaging (10) – cardboard packs.
30 pcs. – contour cell packaging (1) – cardboard packs.
30 pcs. – contour cell packaging (2) – cardboard packs.
30 pcs. – contour cell packaging (3) – cardboard packs.
30 pcs. – contour cell packaging (4) – cardboard packs.
30 pcs. – contour cell packaging (5) – cardboard packs.
30 pcs. – contour cell packaging (6) – cardboard packs.
30 pcs. – contour cell packaging (8) – cardboard packs.
30 pcs. – contour cell packaging (10) – cardboard packs.
Extended-release tablets, film-coated, 1.5 mg: 30 pcs.
Marketing Authorization Holder
Tatkhimpharmpreparaty, JSC (Russia)
Dosage Form
|
Indapamide Retard | Extended-release tablets, film-coated, 1.5 mg: 30 pcs. |
Dosage Form, Packaging, and Composition
| Extended-release tablets, film-coated | 1 tab. |
| Indapamide | 1.5 mg |
10 pcs. – contour cell packs (3) – cardboard packs.
15 pcs. – contour cell packs (2) – cardboard packs.
Film-coated extended-release tablets, 1.5 mg: 30 pcs.
Marketing Authorization Holder
Alkaloid AD (Macedonia)
Dosage Form
|
Indapamide Alkaloid | Film-coated extended-release tablets, 1.5 mg: 30 pcs. |
Dosage Form, Packaging, and Composition
Extended-release tablets, film-coated white or almost white, round, biconvex; the core on the cross-section is white or almost white.
| 1 tab. | |
| Indapamide | 1.5 mg |
Excipients: lactose monohydrate – 129.5 mg, low-viscosity hydroxyethyl cellulose – 6 mg; high-viscosity – 60 mg, colloidal silicon dioxide – 2 mg, magnesium stearate – 1 mg.
Film coating composition hypromellose – 6.01 mg, titanium dioxide – 3.99 mg.
10 pcs. – blisters (3) – cardboard packs.
Film-coated tablets, 2.5 mg: 10, 20, 30, 40, 60, or 90 pcs.
Marketing Authorization Holder
Canonpharma Production, CJS (Russia)
Manufactured By
Canonpharma Production, CJS (Russia)
Or
Raduga Production CJS (Russia)
Dosage Form
|
Indapamide Canon | Film-coated tablets, 2.5 mg: 10, 20, 30, 40, 60, or 90 pcs. |
Dosage Form, Packaging, and Composition
Tablets, film-coated white or almost white, round, biconvex; white on the cross-section.
| 1 tab. | |
| Indapamide | 2.5 mg |
Excipients: potato starch – 18.2 mg, crospovidone (Kollidon CL-M or Kollidon CL) – 0.8 mg, lactose (milk sugar) – 62.5 mg, magnesium stearate – 0.8 mg, povidone (Kollidon 30) – 4.5 mg, talc – 0.7 mg, microcrystalline cellulose – 30 mg.
Film coating composition hypromellose (hydroxypropylcellulose), hypromellose (hydroxypropylmethylcellulose), copovidone (Kollidon VA-64), talc, titanium dioxide.
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (4) – cardboard packs.
30 pcs. – contour cell packs (1) – cardboard packs.
30 pcs. – contour cell packs (2) – cardboard packs.
30 pcs. – contour cell packs (3) – cardboard packs.
Film-coated tablets, 2.5 mg: 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 pcs.
Marketing Authorization Holder
Bright Way, LLC (Russia)
Manufactured By
Velpharm, LLC (Russia)
Or
Velpharm-M, LLC (Russia)
Dosage Form
|
Indapamide CONSUMED | Film-coated tablets, 2.5 mg: 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 pcs. |
Dosage Form, Packaging, and Composition
Tablets, film-coated white or almost white, round, biconvex; on the cross-section – the core is white or almost white.
| 1 tab. | |
| Indapamide | 2.5 mg |
Excipients: lactose monohydrate (milk sugar), corn starch, povidone K25, magnesium stearate, microcrystalline cellulose (type 101).
Film coating composition ready-made dry mix for film coating containing hypromellose, titanium dioxide, macrogol or hypromellose (hydroxypropylmethylcellulose), titanium dioxide, macrogol 6000 (polyethylene glycol 6000, polyethylene oxide 6000).
10 pcs. – contour cell pack (1) – cardboard packs.
10 pcs. – contour cell pack (2) – cardboard packs.
10 pcs. – contour cell pack (3) – cardboard packs.
10 pcs. – contour cell pack (4) – cardboard packs.
10 pcs. – contour cell pack (5) – cardboard packs.
10 pcs. – contour cell pack (6) – cardboard packs.
10 pcs. – polymer jars (1) – cardboard packs.
20 pcs. – polymer jars (1) – cardboard packs.
30 pcs. – polymer jars (1) – cardboard packs.
40 pcs. – polymer jars (1) – cardboard packs.
50 pcs. – polymer jars (1) – cardboard packs.
60 pcs. – polymer jars (1) – cardboard packs.
70 pcs. – polymer jars (1) – cardboard packs.
80 pcs. – polymer jars (1) – cardboard packs.
90 pcs. – polymer jars (1) – cardboard packs.
100 pcs. – polymer jars (1) – cardboard packs.
Film-coated tablets, 2.5 mg: 30 or 100 pcs.
Marketing Authorization Holder
Apotex, Inc. (Canada)
For
NYCOMED AUSTRIA, GmbH (Austria)
Dosage Form
|
Indapamide Nycomed | Film-coated tablets, 2.5 mg: 30 or 100 pcs. |
Dosage Form, Packaging, and Composition
| Tablets, coated | 1 tab. |
| Indapamide | 2.5 mg |
30 pcs. – polyethylene bottles.
100 pcs. – polyethylene bottles.
Film-coated tablets, 2.5 mg: 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 pcs.
Marketing Authorization Holder
Pharmasintez-Tyumen, LLC (Russia)
Dosage Form
|
Indapamide Pharmasyntez | Film-coated tablets, 2.5 mg: 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 pcs. |
Dosage Form, Packaging, and Composition
Tablets, film-coated from white to almost white, round, biconvex, smooth; on the cross-section the tablet core is from white to almost white.
| 1 tab. | |
| Indapamide | 2.5 mg |
Excipients: calcium hydrogen phosphate – 33.333 mg, lactose monohydrate – 26.526 mg, corn starch – 68.666 mg, povidone (K-30) – 3.333 mg, talc – 2.666 mg, sodium lauryl sulfate – 0.8333 mg, magnesium stearate – 2 mg.
Coating composition ready coating VIVACOAT-PC-1P- 404, white – 2.14 mg (hypromellose (HPMC 5) – 70%, macrogol 6000 – 9%, polysorbate 80 (tween 80) – 1%, titanium dioxide – 20%).
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (4) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
10 pcs. – contour cell packs (6) – cardboard packs.
10 pcs. – contour cell packs (7) – cardboard packs.
10 pcs. – contour cell packs (8) – cardboard packs.
10 pcs. – contour cell packs (9) – cardboard packs.
10 pcs. – contour cell packs (10) – cardboard packs.
10 pcs. – polymer jars with first opening control (1) – cardboard packs.
20 pcs. – polymer jars with first opening control (1) – cardboard packs.
30 pcs. – polymer jars with first opening control (1) – cardboard packs.
40 pcs. – polymer jars with first opening control (1) – cardboard packs.
50 pcs. – polymer jars with first opening control (1) – cardboard packs.
60 pcs. – polymer jars with first opening control (1) – cardboard packs.
90 pcs. – polymer jars with first opening control (1) – cardboard packs.
100 pcs. – polymer jars with first opening control (1) – cardboard packs.
Extended-release tablets, film-coated, 1.5 mg: 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 pcs.
Marketing Authorization Holder
Pharmasintez-Tyumen, LLC (Russia)
Dosage Form
|
Indapamide Pharmasyntez | Extended-release tablets, film-coated, 1.5 mg: 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 pcs. |
Dosage Form, Packaging, and Composition
Extended-release tablets, film-coated white, round, biconvex.
| 1 tab. | |
| Indapamide | 1.5 mg |
Excipients: hypromellose K4M – 55 mg, lactose monohydrate – 98.9 mg, povidone (K-30) – 3.2 mg, colloidal silicon dioxide – 0.4 mg, magnesium stearate – 1 mg.
Film coating composition ready coating VIVACOAT-PC-1P-404, white 4.8 mg (hypromellose (HPMC) 5 70%, macrogol 6000 (polyethylene glycol 6000) 9%, polysorbate 80 (tween 80) 1%, titanium dioxide 20%).
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (4) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
10 pcs. – contour cell packs (6) – cardboard packs.
10 pcs. – contour cell packs (7) – cardboard packs.
10 pcs. – contour cell packs (8) – cardboard packs.
10 pcs. – contour cell packs (9) – cardboard packs.
10 pcs. – contour cell packs (10) – cardboard packs.
15 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – polymer jars (1) – cardboard packs.
20 pcs. – polymer jars (1) – cardboard packs.
30 pcs. – polymer jars (1) – cardboard packs.
40 pcs. – polymer jars (1) – cardboard packs.
50 pcs. – polymer jars (1) – cardboard packs.
60 pcs. – polymer jars (1) – cardboard packs.
90 pcs. – polymer jars (1) – cardboard packs.
100 pcs. – polymer jars (1) – cardboard packs.
Extended-release tablets, film-coated, 1.5 mg: 30, 60, or 90 pcs.
Marketing Authorization Holder
Obnovlenie Pfc, JSC (Russia)
Dosage Form
|
Indapamide Renewal | Extended-release tablets, film-coated, 1.5 mg: 30, 60, or 90 pcs. |
Dosage Form, Packaging, and Composition
Extended-release tablets, film-coated white or almost white, round, biconvex; on the cross-section the core is white or almost white.
| 1 tab. | |
| Indapamide | 1.5 mg |
Excipients: lactose monohydrate – 124.5 mg, hypromellose – 64 mg, povidone K30 – 8.6 mg, magnesium stearate – 1 mg, colloidal anhydrous silicon dioxide (aerosil) – 0.4 mg.
Coating composition hypromellose – 3.642 mg, titanium dioxide – 0.701 mg, glycerol – 0.219 mg, macrogol 6000 – 0.219 mg, magnesium stearate – 0.219 mg.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (6) – cardboard packs.
10 pcs. – contour cell packs (9) – cardboard packs.
15 pcs. – contour cell packs (2) – cardboard packs.
15 pcs. – contour cell packs (4) – cardboard packs.
15 pcs. – contour cell packs (6) – cardboard packs.
Tablets, film-coated, 2.5 mg: 28, 30, 60, or 90 pcs.
Marketing Authorization Holder
Obnovlenie Pfc, JSC (Russia)
Dosage Form
|
Indapamide Renewal | Tablets, film-coated, 2.5 mg: 28, 30, 60, or 90 pcs. |
Dosage Form, Packaging, and Composition
Tablets, film-coated white or almost white, round, biconvex; surface roughness is allowed; on the cross-section the core is white or almost white.
| 1 tab. | |
| Indapamide | 2.5 mg |
Excipients: lactose monohydrate, corn starch, povidone K30, talc, magnesium stearate.
Coating composition: hypromellose, titanium dioxide, glycerol, magnesium stearate, macrogol 6000, sodium lauryl sulfate.
10 pcs. – contour cell packs (3) – cardboard packs.
14 pcs. – contour cell packs (2) – cardboard packs.
15 pcs. – contour cell packs (2) – cardboard packs.
15 pcs. – contour cell packs (4) – cardboard packs.
15 pcs. – contour cell packs (6) – cardboard packs.
Extended-release tablets, film-coated, 1.5 mg: 10, 15, 20, 30, 40, 45, 50, 60, 75, 80, 90, 100, 120 or 150 pcs.
Marketing Authorization Holder
Aliym, JSC (Russia)
Dosage Form
|
Indapamide retard-Alium | Extended-release tablets, film-coated, 1.5 mg: 10, 15, 20, 30, 40, 45, 50, 60, 75, 80, 90, 100, 120 or 150 pcs. |
Dosage Form, Packaging, and Composition
Extended-release tablets, film-coated white or almost white, round, biconvex; on the cross-section the core is white or almost white.
| 1 tab. | |
| Indapamide | 1.5 mg |
Excipients: colloidal silicon dioxide (aerosil), hypromellose (hydroxypropylmethylcellulose), copovidone (copovidone), magnesium stearate, lactose monohydrate, microcrystalline cellulose.
Coating composition hypromellose (hydroxypropylmethylcellulose), macrogol 6000 (polyethylene glycol 6000), talc, titanium dioxide.
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (4) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
15 pcs. – contour cell packs (1) – cardboard packs.
15 pcs. – contour cell packs (2) – cardboard packs.
15 pcs. – contour cell packs (3) – cardboard packs.
15 pcs. – contour cell packs (4) – cardboard packs.
15 pcs. – contour cell packs (5) – cardboard packs.
20 pcs. – contour cell packs (1) – cardboard packs.
20 pcs. – contour cell packs (2) – cardboard packs.
20 pcs. – contour cell packs (3) – cardboard packs.
20 pcs. – contour cell packs (4) – cardboard packs.
20 pcs. – contour cell packs (5) – cardboard packs.
30 pcs. – contour cell packs (1) – cardboard packs.
30 pcs. – contour cell packs (2) – cardboard packs.
30 pcs. – contour cell packs (3) – cardboard packs.
30 pcs. – contour cell packs (4) – cardboard packs.
30 pcs. – contour cell packs (5) – cardboard packs.
Extended-release tablets, film-coated 1.5 mg
Marketing Authorization Holder
Alsi Pharma, JSC (Russia)
Dosage Form
|
Indapamide retard-Alsi | Extended-release tablets, film-coated 1.5 mg |
Dosage Form, Packaging, and Composition
Extended-release tablets, film-coated
| Indapamide | 1.5 mg |
10 pcs. – contour cell packs – cardboard packs (10 pcs.) – By prescription
10 pcs. – contour cell packs (2 pcs.) – cardboard packs (20 pcs.) – By prescription
10 pcs. – contour cell packs (3 pcs.) – cardboard packs (30 pcs.) – By prescription
10 pcs. – contour cell packs (4 pcs.) – cardboard packs (40 pcs.) – By prescription
10 pcs. – contour cell packs (5 pcs.) – cardboard packs (50 pcs.) – By prescription
10 pcs. – contour cell packs (6 pcs.) – cardboard packs (60 pcs.) – By prescription
10 pcs. – contour cell packs (9 pcs.) – cardboard packs (90 pcs.) – By prescription
Extended-release tablets, film-coated, 1.5 mg: 10, 20, 30, 40, 50, 60, 80 or 100 pcs.
Marketing Authorization Holder
FP Obolenskoe, JSC (Russia)
Dosage Form
|
Indapamide Retard-OBL | Extended-release tablets, film-coated, 1.5 mg: 10, 20, 30, 40, 50, 60, 80 or 100 pcs. |
Dosage Form, Packaging, and Composition
| Extended-release tablets, film-coated | 1 tab. |
| Indapamide | 1.5 mg |
10 pcs. – contour cell packaging (1) – cardboard packs.
10 pcs. – contour cell packaging (2) – cardboard packs.
10 pcs. – contour cell packaging (3) – cardboard packs.
10 pcs. – contour cell packaging (4) – cardboard packs.
10 pcs. – contour cell packaging (5) – cardboard packs.
10 pcs. – contour cell packaging (6) – cardboard packs.
10 pcs. – contour cell packaging (8) – cardboard packs.
10 pcs. – contour cell packaging (10) – cardboard packs.
Extended-release tablets, film-coated, 1.5 mg: 10, 20, 30, 50, 90, or 100 pcs.
Marketing Authorization Holder
Teva Pharmaceutical Industries, Ltd. (Israel)
Manufactured By
Merckle, GmbH (Germany)
Dosage Form
|
Indapamide retard-Teva | Extended-release tablets, film-coated, 1.5 mg: 10, 20, 30, 50, 90, or 100 pcs. |
Dosage Form, Packaging, and Composition
Extended-release tablets, film-coated white or almost white, round, biconvex; on the cross-section, the tablet core is white or almost white.
| 1 tab. | |
| Indapamide | 1.5 mg |
Excipients: lactose monohydrate – 119.1 mg, hypromellose – 77.4 mg, colloidal silicon dioxide – 1 mg, magnesium stearate – 1 mg.
Shell composition: hypromellose – 5 mg, glycerol 85% – 0.7 mg, titanium dioxide – 1 mg.
10 pcs. – blisters (1) – cardboard packs×.
10 pcs. – blisters (2) – cardboard packs×.
10 pcs. – blisters (3) – cardboard packs×.
10 pcs. – blisters (5) – cardboard packs×.
10 pcs. – blisters (9) – cardboard packs×.
10 pcs. – blisters (10) – cardboard packs×.
× protective stickers may be additionally applied to the packs.
Extended-release tablets, film-coated, 1.5 mg: 30, 60 or 90 pcs.
Marketing Authorization Holder
Sandoz, d.d. (Slovenia)
Dosage Form
|
Indapamide Sandoz | Extended-release tablets, film-coated, 1.5 mg: 30, 60 or 90 pcs. |
Dosage Form, Packaging, and Composition
Extended-release tablets, film-coated white, round, biconvex; on the cross-section, the core is white.
| 1 tab. | |
| Indapamide | 1.5 mg |
Excipients: lactose monohydrate 108.6 mg, hypromellose 40 mg, povidone K30 8 mg, colloidal silicon dioxide 0.4 mg, microcrystalline cellulose 40 mg, magnesium stearate 1.5 mg.
Film coating composition: Selecote AQ-02003 5 mg (hypromellose 55-65 %, macrogol 6000 15-25 %, titanium dioxide 15-25 %).
10 pcs. – blisters made of PVC/PVDC/aluminum foil (3) – cardboard packs.
10 pcs. – blisters made of PVC/PVDC/aluminum foil (6) – cardboard packs.
10 pcs. – blisters made of PVC/PVDC/aluminum foil (9) – cardboard packs.
10 pcs. – Al/Al blisters (3) – cardboard packs.
10 pcs. – Al/Al blisters (6) – cardboard packs.
10 pcs. – Al/Al blisters (9) – cardboard packs.
Film-coated tablets, 2.5 mg: 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 pcs.
Marketing Authorization Holder
Velpharm, LLC (Russia)
Manufactured By
Velpharm, LLC (Russia)
Or
Velpharm-M, LLC (Russia)
Dosage Form
|
Indapamide Velpharm | Film-coated tablets, 2.5 mg: 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 pcs. |
Dosage Form, Packaging, and Composition
Tablets, film-coated white or almost white, round, biconvex; on the cross-section – the core is white or almost white.
| 1 tab. | |
| Indapamide | 2.5 mg |
Excipients: lactose monohydrate (milk sugar), corn starch, povidone K25, magnesium stearate, microcrystalline cellulose.
Shell composition ready dry mixture for film coating, containing hypromellose, titanium dioxide, macrogol.
10 pcs. – contour cell packaging (1) – cardboard packs.
10 pcs. – contour cell packaging (2) – cardboard packs.
10 pcs. – contour cell packaging (3) – cardboard packs.
10 pcs. – contour cell packaging (4) – cardboard packs.
10 pcs. – contour cell packaging (5) – cardboard packs.
10 pcs. – contour cell packaging (6) – cardboard packs.
10 pcs. – polymer jars (1) – cardboard packs.
20 pcs. – polymer jars (1) – cardboard packs.
30 pcs. – polymer jars (1) – cardboard packs.
40 pcs. – polymer jars (1) – cardboard packs.
50 pcs. – polymer jars (1) – cardboard packs.
60 pcs. – polymer jars (1) – cardboard packs.
70 pcs. – polymer jars (1) – cardboard packs.
80 pcs. – polymer jars (1) – cardboard packs.
90 pcs. – polymer jars (1) – cardboard packs.
100 pcs. – polymer jars (1) – cardboard packs.
Film-coated tablets 2.5 mg
Marketing Authorization Holder
Velpharm, LLC (Russia)
Manufactured By
Velpharm, LLC (Russia)
Or
Velpharm-M, LLC (Russia)
Dosage Form
|
Indapamide Velpharm | Film-coated tablets 2.5 mg |
Dosage Form, Packaging, and Composition
Tablets, film-coated
| 1 tab. | |
| Indapamide | 2.5 mg |
1 kg – bags – fiber drums – In-Bulk
1 kg – bags – plastic buckets – In-Bulk
10 pcs. – jars – cardboard packs (10 pcs.) – By prescription
10 pcs. – contour cell packaging – cardboard packs (10 pcs.) – By prescription
10 pcs. – contour cell packaging (100 pcs.) – cardboard container (1000 pcs.) – In-Bulk
10 pcs. – contour cell packaging (1000 pcs.) – cardboard container (10000 pcs.) – In-Bulk
10 pcs. – contour cell packaging (1500 pcs.) – cardboard container (15000 pcs.) – In-Bulk
10 pcs. – contour cell packaging (2 pcs.) – cardboard packs (20 pcs.) – By prescription
10 pcs. – contour cell packaging (200 pcs.) – cardboard container (2000 pcs.) – In-Bulk
10 pcs. – contour cell packaging (2000 pcs.) – cardboard container (20000 pcs.) – In-Bulk
10 pcs. – contour cell packaging (2500 pcs.) – cardboard container (25000 pcs.) – In-Bulk
10 pcs. – contour cell packaging (3 pcs.) – cardboard packs (30 pcs.) – By prescription
10 pcs. – contour cell packaging (300 pcs.) – cardboard container (3000 pcs.) – In-Bulk
10 pcs. – contour cell packaging (3000 pcs.) – cardboard container (30000 pcs.) – In-Bulk
10 pcs. – contour cell packaging (3500 pcs.) – cardboard container (35000 pcs.) – In-Bulk
10 pcs. – contour cell packaging (4 pcs.) – cardboard packs (40 pcs.) – By prescription
10 pcs. – contour cell packaging (400 pcs.) – cardboard container (4000 pcs.) – In-Bulk
10 pcs. – contour cell packaging (4000 pcs.) – cardboard container (40000 pcs.) – In-Bulk
10 pcs. – contour cell packaging (4500 pcs.) – cardboard container (45000 pcs.) – In-Bulk
10 pcs. – contour cell packaging (5 pcs.) – cardboard packs (50 pcs.) – By prescription
10 pcs. – contour cell packaging (500 pcs.) – cardboard container (5000 pcs.) – In-Bulk
10 pcs. – contour cell packaging (5000 pcs.) – cardboard container (50000 pcs.) – In-Bulk
10 pcs. – contour cell packaging (6 pcs.) – cardboard packs (60 pcs.) – By prescription
10 pcs. – contour cell packaging (600 pcs.) – cardboard container (6000 pcs.) – In-Bulk
10 pcs. – contour cell packaging (700 pcs.) – cardboard container (7000 pcs.) – In-Bulk
10 pcs. – contour cell packaging (800 pcs.) – cardboard container (8000 pcs.) – In-Bulk
10 pcs. – contour cell packaging (900 pcs.) – cardboard container (9000 pcs.) – In-Bulk
100 pcs. – jars – cardboard packs (100 pcs.) – By prescription
2 kg – bags – fiber drums – In-Bulk
2 kg – bags – plastic buckets – In-Bulk
20 pcs. – jars – cardboard packs (20 pcs.) – By prescription
3 kg – bags – fiber drums – In-Bulk
3 kg – bags – plastic buckets – In-Bulk
30 pcs. – jars – cardboard packs (30 pcs.) – By prescription
4 kg – bags – fiber drums – In-Bulk
4 kg – bags – plastic buckets – In-Bulk
40 pcs. – jars – cardboard packs (40 pcs.) – By prescription
5 kg – bags – fiber drums – In-Bulk
5 kg – bags – plastic buckets – In-Bulk
50 pcs. – jars – cardboard packs (50 pcs.) – By prescription
60 pcs. – jars – cardboard packs (60 pcs.) – By prescription
70 pcs. – jars – cardboard packs (70 pcs.) – By prescription
80 pcs. – jars – cardboard packs (80 pcs.) – By prescription
90 pcs. – jars – cardboard packs (90 pcs.) – By prescription
Film-coated tablets, 2.5 mg: 10, 20, 30, 40, 50 or 60 pcs.
Marketing Authorization Holder
Veltrade, LLC (Russia)
Manufactured By
Velpharm, LLC (Russia)
Dosage Form
|
Indapamide VT | Film-coated tablets, 2.5 mg: 10, 20, 30, 40, 50 or 60 pcs. |
Dosage Form, Packaging, and Composition
Tablets, film-coated white or almost white, round, biconvex; on the cross-section – the core is white or almost white.
| 1 tab. | |
| Indapamide | 2.5 mg |
Excipients: lactose monohydrate, corn starch, povidone K25, magnesium stearate, microcrystalline cellulose type 101.
Shell composition Opadry® 03F180011 white (hypromellose, titanium dioxide, macrogol, or hypromellose (hydroxypropyl methylcellulose), titanium dioxide, macrogol 6000 (polyethylene glycol 6000, polyethylene oxide 6000)).
10 pcs. – contour cell packaging (1) – cardboard pack.
10 pcs. – contour cell packaging (2) – cardboard pack.
10 pcs. – contour cell packaging (3) – cardboard pack.
10 pcs. – contour cell packaging (4) – cardboard pack.
10 pcs. – contour cell packaging (5) – cardboard pack.
10 pcs. – contour cell packaging (6) – cardboard pack.
10 pcs. – jars – cardboard packs.
20 pcs. – jars – cardboard packs.
30 pcs. – jars – cardboard packs.
40 pcs. – jars – cardboard packs.
50 pcs. – jars – cardboard packs.
60 pcs. – jars – cardboard packs.
Tablets, film-coated, 2.5 mg: 20, 30, or 60 pcs.
Marketing Authorization Holder
Polpharma Pharmaceutical Works, Sa (Poland)
Manufactured By
Pharmaceutical Works “Polpharma”, SA (Poland)
Labeled By
Pharmaceutical Works “POLPHARMA”, SA (Poland)
Or
Akrikhin Chemical and Pharmaceutical Plant, JSC (Russia)
Quality Control Release
Pharmaceutical Works “POLPHARMA”, SA (Poland)
Dosage Form
|
Indapamide-Akrikhin | Tablets, film-coated, 2.5 mg: 20, 30, or 60 pcs. |
Dosage Form, Packaging, and Composition
Tablets, film-coated white, with a slightly rough surface, round, biconvex.
| 1 tab. | |
| Indapamide | 2.5 mg |
Excipients: microcrystalline cellulose, crospovidone, magnesium stearate.
Film coating composition Sepifilm LP770 white (hypromellose, microcrystalline cellulose, stearic acid, titanium dioxide).
10 pcs. – blisters (2) – cardboard packs.
10 pcs. – blisters (3) – cardboard packs.
10 pcs. – blisters (6) – cardboard packs.
Film-coated tablets, 2.5 mg: 10, 15, 20, 30, 40, 45, 60 or 90 pcs.
Marketing Authorization Holder
Aliym, JSC (Russia)
Dosage Form
|
Indapamide-Alium | Film-coated tablets, 2.5 mg: 10, 15, 20, 30, 40, 45, 60 or 90 pcs. |
Dosage Form, Packaging, and Composition
Tablets, film-coated white or almost white, round, biconvex; on the cross-section the core is white or almost white.
| 1 tab. | |
| Indapamide | 2.5 mg |
Excipients: lactose monohydrate, microcrystalline cellulose (Vivapur 101), sodium carboxymethyl starch (sodium starch glycolate), povidone K30, magnesium stearate.
Shell composition hypromellose (hydroxypropyl methylcellulose), macrogol 6000 (polyethylene glycol 6000), titanium dioxide.
10 pcs. – contour cell packaging (1) – cardboard packs.
10 pcs. – contour cell packaging (2) – cardboard packs.
10 pcs. – contour cell packaging (3) – cardboard packs.
15 pcs. – contour cell packaging (1) – cardboard packs.
15 pcs. – contour cell packaging (2) – cardboard packs.
15 pcs. – contour cell packaging (3) – cardboard packs.
20 pcs. – contour cell packaging (1) – cardboard packs.
20 pcs. – contour cell packaging (2) – cardboard packs.
20 pcs. – contour cell packaging (3) – cardboard packs.
30 pcs. – contour cell packaging (1) – cardboard packs.
30 pcs. – contour cell packaging (2) – cardboard packs.
30 pcs. – contour cell packaging (3) – cardboard packs.
Tablets, film-coated, 2.5 mg: 10, 20, 30, 40, 50, 60, or 90 pcs.
Marketing Authorization Holder
Alsi Pharma, JSC (Russia)
Dosage Form
|
Indapamide-ALSI | Tablets, film-coated, 2.5 mg: 10, 20, 30, 40, 50, 60, or 90 pcs. |
Dosage Form, Packaging, and Composition
Tablets, film-coated white, biconvex shape, on the cross-section – the inner layer is white or white with a creamy tint.
| 1 tab. | |
| Indapamide | 2.5 mg |
Excipients: microcrystalline cellulose – 45 mg, pregelatinized starch – 41.8 mg, colloidal silicon dioxide (aerosil) – 0.5 mg, magnesium stearate – 0.2 mg.
Film coating composition Opadry II (series 31F28678 White) [lactose monohydrate – 1.3 mg, hypromellose – 1.01 mg, titanium dioxide – 0.93 mg, macrogol – 0.36 mg] – 3.6 mg.
10 pcs. – contour cell packaging (1) – cardboard packs.
10 pcs. – contour cell packaging (2) – cardboard packs.
10 pcs. – contour cell packaging (3) – cardboard packs.
10 pcs. – contour cell packaging (4) – cardboard packs.
10 pcs. – contour cell packaging (5) – cardboard packs.
10 pcs. – contour cell packaging (6) – cardboard packs.
10 pcs. – contour cell packaging (9) – cardboard packs.
Film-coated extended-release tablets, 1.5 mg: 20, 30, or 60 pcs.
Marketing Authorization Holder
Krka-Rus, LLC (Russia)
Dosage Form
|
Indapamide-KRKA | Film-coated extended-release tablets, 1.5 mg: 20, 30, or 60 pcs. |
Dosage Form, Packaging, and Composition
Extended-release tablets, film-coated white or almost white, round, slightly biconvex.
| 1 tab. | |
| Indapamide | 1.5 mg |
Excipients: hypromellose, cellactose [lactose monohydrate, cellulose], povidone K30, colloidal silicon dioxide, magnesium stearate.
Film coating composition Opadry Y-1-7000 (hypromellose, titanium dioxide, macrogol 400).
10 pcs. – contour cell packaging (2) – cardboard packs.
10 pcs. – contour cell packaging (3) – cardboard packs.
10 pcs. – contour cell packaging (6) – cardboard packs.
Tablets, film-coated, 2.5 mg: 30 pcs.
Marketing Authorization Holder
Teva Pharmaceutical Industries, Ltd. (Israel)
Manufactured By
Balkanpharma-Razgrad, AD (Bulgaria)
Dosage Form
|
Indapamide-Teva | Tablets, film-coated, 2.5 mg: 30 pcs. |
Dosage Form, Packaging, and Composition
Tablets, film-coated white or almost white, biconvex; the core on the cross-section is white or almost white.
| 1 tab. | |
| Indapamide hemihydrate | 2.5 mg |
Excipients: lactose monohydrate – 63.5 mg, corn starch – 20 mg, povidone K30 – 7 mg, calcium hydrogen phosphate dihydrate – 3 mg, magnesium stearate – 1.5 mg, talc – 2.5 mg.
Film coating composition opadry (Opadry® White OY-B-28920) – 2.5 mg (polyvinyl alcohol – 45.52%, titanium dioxide (E171) – 32%, talc – 20%, soy lecithin – 2%, xanthan gum – 0.48%).
10 pcs. – blisters (3) – carton packs×.
× protective stickers may be additionally applied.
Capsules 2.5 mg: 30, 50, or 100 pcs.
Marketing Authorization Holder
Teva Pharmaceutical Industries, Ltd. (Israel)
Manufactured By
Merckle, GmbH (Germany)
Dosage Form
|
Indapamide-Teva | Capsules 2.5 mg: 30, 50, or 100 pcs. |
Dosage Form, Packaging, and Composition
Capsules hard gelatin, size No. 4, opaque; capsule body – pink, cap – brown; capsule contents – white or almost white powder.
| 1 tab. | |
| Indapamide anhydrous (in the form of indapamide hemihydrate) | 2.44 mg (2.5 mg) |
Excipients: lactose monohydrate – 60.06 mg, corn starch – 60 mg, sodium carboxymethyl starch – 6.25 mg, magnesium stearate – 2.5 mg.
Composition of the hard gelatin capsule body gelatin – 22.0899 mg, titanium dioxide – 0.456 mg, iron oxide red dye – 0.1661 mg, iron oxide yellow dye – 0.0879 mg.
Composition of the hard gelatin capsule cap gelatin – 14.9796 mg, titanium dioxide – 0.0608 mg, iron oxide red dye – 0.114 mg, iron oxide black dye – 0.0456 mg.
10 pcs. – blisters (3) – carton packs×.
10 pcs. – blisters (5) – carton packs×.
10 pcs. – blisters (10) – carton packs×.
× protective stickers may be additionally applied.
Capsules 2.5 mg: 30 pcs.
Marketing Authorization Holder
Vertex, JSC (Russia)
Dosage Form
|
Indapamide-Verte | Capsules 2.5 mg: 30 pcs. |
Dosage Form, Packaging, and Composition
| Capsules | 1 caps. |
| Indapamide | 2.5 mg |
10 pcs. – contour cell packs (3) – carton packs.
30 pcs. – polymer jars (1) – carton packs.
Capsules 2.5 mg: 10, 14, 20, 28, 30, 42, 50, 56, or 60 pcs.
Marketing Authorization Holder
Vertex, JSC (Russia)
Dosage Form
|
Indapamide-Vertex | Capsules 2.5 mg: 10, 14, 20, 28, 30, 42, 50, 56, or 60 pcs. |
Dosage Form, Packaging, and Composition
Capsules hard gelatin, size No. 3, with a white body and an orange cap; capsule contents – powder or compacted mass of white or white with a yellowish tint, disintegrating when pressed with a glass rod.
| 1 tab. | |
| Indapamide | 2.5 mg |
Excipients: lactose monohydrate – 143 mg, povidone K17 (low molecular weight polyvinylpyrrolidone) – 2 mg, corn starch – 1.5 mg, sodium lauryl sulfate – 0.5 mg, calcium stearate – 0.5 mg.
Composition of the capsule body titanium dioxide – 2%, gelatin – up to 100%.
Composition of the capsule cap titanium dioxide – 2%, azorubine dye – 0.0328%, sunset yellow FCF dye – 0.219%, gelatin – up to 100%.
10 pcs. – contour cell packs (1) – carton packs.
10 pcs. – contour cell packs (2) – carton packs.
10 pcs. – contour cell packs (3) – carton packs.
10 pcs. – contour cell packs (5) – carton packs.
10 pcs. – contour cell packs (6) – carton packs.
14 pcs. – contour cell packs (1) – carton packs.
14 pcs. – contour cell packs (2) – carton packs.
14 pcs. – contour cell packs (3) – carton packs.
14 pcs. – contour cell packs (4) – carton packs.
![Indapamide [Tablets, Capsules] 1](https://www.medixlife.com/wp-content/uploads/Medixlife_favi_512.png "Indapamide [Tablets, Capsules] 2")